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RESUMO – Introdução: A hidradenite supurativa (HS) é uma dermatose crónica com um grande impacto na qualidade de vida 
dos doentes e um atraso diagnóstico estimado em 7 anos. O médico de medicina geral e familiar (MGF) é geralmente o primeiro 
médico a quem o doente com HS recorre. O objetivo principal deste estudo é descrever o conhecimento e a abordagem clínica 
da HS pelos MGF em Portugal. Material e Métodos: Foi realizado um estudo transversal, com base nas respostas dos MGF a um 
questionário elaborado para avaliar seus conhecimentos sobre HS. Resultados: Cento e oitenta e setenta questionários foram 
considerados válidos para inclusão no estudo. A maioria (97,3%) dos MGF identificou corretamente a HS como o diagnóstico 
mais provável quando confrontado com uma história clínica típica da doença, e 84,5% associaram a HS a cronicidade. A maioria 
(84,0%) dos clínicos referencia esses pacientes, principalmente à Dermatologia (89,3%). A maioria dos médicos também conside-
rou que uma abordagem cirúrgica pode não ser curativa (94,1%) e apenas 15,0% considerarou que agentes biológicos podem ter 
indicação terapêutica. Compararam-se as respostas de 2 grupos: grupo A, n = 100, com <5 anos de prática clínica e grupo B, n 
=	84,	com	≥5	anos.	O	grupo	A	associou	mais	HS	ao	tabagismo	e	obesidade	do	que	o	grupo	B	(p	=	0,013	e	p	=	0,006,	respeti-
vamente). Uma abordagem multidisciplinar também foi mais frequentemente selecionada pelo grupo A (p = 0,004). Conclusão: 
Este estudo piloto mostra que a visão dos MGF portugueses sobre HS pode ser melhorada. Existem diferenças significativas no que 
se refere ao conhecimento de HS entre os médicos com menos de 5 anos de prática clínica e os mais experientes. Este estudo pode 
ajudar a direcionar futuras ações educativas.
PALAVRAS-CHAVE – Clínicos Gerais; Hidradenite Supurativa; Inquéritos e Questionários; Padrões de Prática Médica.
VENUS Study: ViEw of HidradeNitis SuppUrativa by 
PortugueSe General Practitioners 
ABSTRACT – Introduction: Hidradenitis suppurativa (HS) is a chronic dermatosis with a large impact in patients’ quality of life and 
an estimated 7-year delay in diagnosis. The General Practitioner (GP) is usually the first doctor to assist the HS patient. The primary 
objective of this study is to describe the knowledge and clinical approach of HS by GPs. Material and Methods: A cross-sectional 
study was conducted, based on the GPs answers to a questionnaire designed to evaluate their knowledge on HS. Results: One hun-
dred eighty seven questionnaires were considered valid for inclusion in the study. The majority (97.3%) of GPs correctly identified HS 
as the most likely diagnosis when confronted with a typical clinical history of the disease, and 84.5% associated HS with chronicity. 
The majority (84.0%) of GPs refers these patients, mostly to Dermatology (89.3%). The majority of GPs also considered that a surgical 
approach may not be curative (94.1%) and 15.0% considered that biological agents might be indicated. We compared the answers of 
2 groups: group A, n=100, with <5 years of clinical practice and group B, n=84, with ≥5 years. Group A associated more HS with 
tobacco use and obesity than group B (p=0.013 and p=0.006, respectively). A multidisciplinary approach was also more frequen-
tly selected by group A (p=0.004). Conclusion: This pilot study shows that the view of Portuguese GPs about HS can be improved. 
There are significant differences concerning knowledge on HS between GPs with less than 5 years of clinical practice and the more 
experienced ones. This study can help to direct differential future educational actions.  
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INTRODUCTION
Hidradenitis suppurativa (HS) is a chronic inflammatory 
skin disease usually presenting on the second to fourth deca-
des of life with recurrent inflammatory painful subcutaneous 
nodules located in intertriginous areas, i.e., axilla, inguinal 
folds, anogenital and sub-mammary areas. The nodules can 
suppurate, drain and form fistulas and scars. HS pathophy-
siology remains to be fully understood but it is regarded as a 
follicular-based immune-mediated disease. The initial event 
is thought to be follicular occlusion, with cyst formation and 
intense inflammatory response when it ruptures.1
There is a well-known association of HS with obesity and 
smoking, as well as metabolic syndrome, and a nearly dou-
bled risk of cardiovascular associated-death has been found 
in HS patients when compared to controls.2 Additionally, the 
coexistence of other inflammatory diseases such as inflam-
matory bowel disease, psoriasis, or spondyloarthritis has 
been described.3-5
HS greatly impacts self-esteem and patients’ quality of 
life (QoL), having more impact than other dermatological 
conditions.6 Patients report QoL impairment due to chroni-
city, recurrence and pain resulting from skin inflammation 
which can also lead to scarring and disfigurement. Moreo-
ver, the lesions affect intimate body regions, with great im-
pact in patients’ social and private life.7,8 In line with this, 
patients with HS have a high psychiatric disease burden9 
and a higher risk of depression and suicide.10-12 
Proper disease recognition and early diagnosis are of 
paramount importance since they will allow for early treat-
ment, which may delay disease progression, namely fibrosis 
and scar tissue formation. Additionally, treatment costs and 
complexity increase with disease severity, and early diagno-
sis of HS is also considered to be cost-effective.13 
In the Portuguese National Healthcare System, the gene-
ral practitioner (GP) acts as a gatekeeper, being the first phy-
sician that usually observes patients. Whenever needed, GPs 
refer the patient to other medical specialties for specialized 
clinical management. Few studies have evaluated the GPs’ 
level of knowledge on HS. Benhadou et al have shown that 
Belgian and Danish GPs need more training on HS,14 but no 
such data is available concerning the Portuguese reality. The-
refore, the aim of this study was to describe the knowledge on 
and clinical approach of HS by Portuguese GPs.
MATERIAL AND METHODS
Data collection
A cross-sectional study was conducted, based on a 
questionnaire specifically designed to evaluate GPs general 
knowledge regarding HS. This questionnaire was translated 
and adapted from Benhadou et al.14 A total of sixteen ques-
tions, five demographic and eleven concerning the disease, 
with a first question to choose the correct diagnosis based 
on the clinical history of a typical case, and then diagno-
sis, pathophysiology, prevalence and clinical approach were 
answered by the participating GPs – Table 1. Questionnaires 
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Tabe 1 - Questionnaire given to Portuguese General 
Practitioners (adapted from14). 
QUESTION 1 Gender: M/F
QUESTION 2 Year of birth
QUESTION 3 Year of end of medical studies
QUESTION 4 Year of start of practicing medicine
QUESTION 5
How many patients do you have per week
a. Less than 50
b. Between 51 and 100
c. Between 101 and 200
d. More than 200
QUESTION 6
Mrs. DS., 39 years old, has had chronic recur-
rent abcesses for the last 20 years in the right 
and left axilla. The lesions are painful and 
suppurative (with occasional elimination of 
purulent exsudate). Over the years, some le-
sions originated hypertrophic scars. On the last 
year, the patient has developed similar lesions, 
bilaterally, in the groins. Which of the following 
is the most likely diagnosis?
a. Furunculosis
b. Cutaneous tuberculosis
c. Lymphogranuloma venereum
d. Hidradenitis suppurativa
e. Epidermic infected cysts
f. Other bacterial infection
QUESTION 7
The diagnosis of hidradenitis suppurativa is 
mainly:
a. Clinical
b. Analytical (microbiology)
c. Histological
d. Imagiological (ultrasound) 
QUESTION 8
Choose the word(s) associated with hidradenitis 
suppurativa:
a. Chronicity
b. Inflammation
c. Infection
d. Poor hygiene
e. Furunculosis and abcesses
f. Handicap
g. Use of intravenous drugs
h. Antibiotics
i. Surgery
j. Lasertherapy
k. Biological therapy
l. Tobacco use
m. Obesity
QUESTION 9
What is the prevalence of hidradenitis suppura-
tiva in the general population?
a. 1/100
b. 1/1,000
c. 1/100,000
d. 1/500
QUESTION 10
How many patients suffering from hidradenitis 
suppurativa have you encountered in your 
career?
a. 0
b. 1-5
c. 6-10
d. 11-20
e. >20
QUESTION 11
Do you manage hidradenitis suppurativa’s 
patients yourself?
a. Yes
b. No
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were handed to GPs that agreed to participate in the study, 
during the “9os Encontros em Dermatologia e Dermocosmé-
tica” (Lisbon) and “Atualização em Medicina Geral e Fami-
liar AAP 2017” (Coimbra), when both meetings took place, 
in 2017. The former meeting was about General Dermato-
logy and included a lecture about HS; the latter concerned 
several medical specialties and had a lecture about HS. The 
questionnaires were answered individually and collected by 
the investigators before the HS lecture was given. The in-
vestigators collected a total of 209 questionnaires, of which 
187 seven questionnaires (89.5%) were considered valid for 
inclusion in the study.
Statistical analysis
Non-parametric statistical methods were used. Values 
are presented as median (IQR) or n (%), as appropriate. The 
χ2 test was used for comparison of proportions. The Mann-
-Whitney test was used to compare two groups of GPs: those 
with	<5	years	of	clinical	practice	and	those	with	≥5	years	
of clinical practice. The Bonferroni correction was applied 
whenever necessary. Data analysis was performed using 
SPSSv20 (IBM, USA). Tests were considered significant at 
α=0.05 significance level (two-sided).
RESULTS
Demographic characteristics of the whole population 
sample and subgroups by years of clinical practice using a 
cut-off of 5 years
One hundred and eighty-seven questionnaires were 
considered valid to be included in the study. Table 2 descri-
bes the demographic characteristics of the studied popula-
tion sample. There were no gender differences. The fact that 
age	and	years	of	practice	were	higher	in	the	group	with	≥5	
years of practice is only a confirmatory internal variable. The 
observation that GPs with more years of practice see more 
patients per week was also to be expected.
Participant’s responses to questionnaire by years of clini-
cal practice using a cut-off  of 5 years
There were a few differences when comparing GPs with 
less	than	5	years	of	clinical	practice	with	GPs	with	≥5	years	
of clinical practice – Table 3. Of notice, younger GPs asso-
ciated more tobacco use and obesity to HS. More experien-
ced GPs manage HS patients by themselves more frequently. 
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QUESTION 12
When you decide to refer hidradenitis sup-
purativa’s patients to other specialists, which 
specialty do you consider to be better prepared 
to manage this disease?
a. Dermatology
b. General Surgery
c. Plastic and Reconstructive Surgery
d. Internal Medicine
e. Specialty in infectious diseases
f. Other. Which one?
QUESTION 13
If you refer to the case in question 6, and as-
suming this was your fist appointment with this 
patient, what course of action would you take?
a. Immediate referral plus immediate treatment
b. Would try to treat without referring
c. Would neither refer nor treat
d. Immediate referral without initiating treat-
ment
Question 14
If you refer to the case in question 6, which 
treatment would you recommend?
a. Topical disinfection and daily bandages
b. Topical antibiotics
c. Systemic antibiotics
d. Surgical excision
e. Surgical incision
f. Immunosuppressive therapy
g. Would not initiate treatment
Question 15
Do you consider that a surgical approach guar-
antees the cure of hidradenitis suppurativa?
a. Yes
b. No
Question 16
Do you think that the management of hidrad-
enitis suppurativa is:
a. Easy
b. Complicated
c. May need a multidisciplinary approach
Table 2 - Demographic characteristics of the whole population sample and by years of clinical practice using a 
cut-off of 5 years.  
Variable Whole population sample <5 years of practice ≥5 years of practice p-value*
# participants 187 100 84
Gender, female 143 (76.5) 74 (74.0) 66 (78.6) 0.469
Age, years 31.0 (12.0) 28.0 (3.0) 42.0 (25.0) <0.001
Years of practice 4.0 (13.0) 2.0 (2.0) 15.0 (25.0) <0.001
# patients/week
<50
51-100
101-200
>200
41 (21.9)
67 (35.8)
64 (34.2)
15 (8.0)
31 (31.0)
44 (44.0)
21 (21.0)
4 (4.0)
9 (10.7)
23 (27.4)
41 (48.8)
11 (13.1)
<0.001
*p-value pertains to comparisons between years of clinical practice. Median (IQR) presented for continuous variables; n (%) for proportions. The Mann-Whitney U test 
was used to compare continuous variables between groups; the χ2 square test was used to compare proportions.
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Table 3 - Participant’s responses to questionnaire by years of clinical practice using a cut-off  of 5 years.  
General Practitioner <5 years of practice ≥5 years of practice p-value*
6. Correct diagnosis of HS 98 (98.0) 81 (96.4) 0.154
7. Diagnosis of HS
Clinical
Analytical
Histological
Imagiological
97 (97.0)
1 (1.0)
2 (2.0)
0 (0.0)
84 (100.0)
0 (0.0)
0 (0.0)
0 (0.0)
0.278
8. Characterization of HS
Chronicity
Inflammation
Infection
Poor hygiene
Furunculosis and abcesses
Handicap
Use of intravenous drugs
Antibiotics
Surgery
Laser therapy
Biological therapy
Tobacco use
Obesity
87 (87.0)
89 (89.0)
43 (43.0)
8 (8.0)
59 (59.0)
45 (45.0)
1 (1.0)
35 (35.0)
33 (33.0)
24 (24.0)
15 (15.0)
54 (54.0)
72 (72.0)
69 (82.1)
77 (91.7)
36 (42.9)
4 (4.8)
48 (57.1)
36 (42.9)
0 (0.0)
36 (42.9)
27 (32.1)
17 (20.2)
13 (15.5)
30 (35.7)
44 (52.4)
0.361
0.544
0.984
0.376
0.799
0.771
0.358
0.275
0.902
0.541
0.929
0.013
0.006
9. Correct prevalence of HS 50 (50.0) 39 (46.4) 0.617
10. Number of HS patients in career
0
1-5
6-10
11-20
                                                     >20
49 (49.0)
46 (46.0)
5 (5.0)
0 (0.0)
0 (0.0)
15 (17.9)
47 (56.0)
12 (14.3)
4 (4.8)
6 (7.1)
<0.001
>0.050
<0.001
<0.001
<0.001
11. Management of HS patients by themselves 5 (5.0) 16 (19.0) 0.002
12. Referral to other specialties*
Dermatology
General Surgery
Plastic and Reconstructive Surgery
Internal Medicine
Specialty in infectious diseases
Other
93 (93.0)
4 (4.0)
3 (3.0)
0 (0.0)
0 (0.0)
0 (0.0)
71 (84.5)
6 (7.1)
3 (3.6)
0 (0.0)
2 (2.4)
2 (2.4)
0.040
13. Course of action
Immediate referral plus immediate treatment
Would try to treat without referring
Would neither refer nor treat
Immediate referral without initiating treatment
Does not know/Does not answer
71 (71.0)
19 (19.0)
0 (0.0)
7 (7.0)
3 (3.0)
51 (60.7)
20 (23.8)
1 (1.2)
10 (11.9)
2 (2.4)
0.452
14. Therapeutical options
Topical disinfection and daily bandages
Topical antibiotics
Systemic antibiotics
Surgical excision
Surgical incision
Immunosuppressive therapies
Would not initiate treatment
31 (31.0)
50 (50.0)
53 (53.0)
6 (6.0)
14 (14.0)
7 (7.0)
7 (7.0)
27 (32.1)
31 (36.9)
55 (65.5)
4 (4.8)
9 (10.7)
1 (1.2)
5 (6.0)
0.868
0.075
0.087
0.712
0.502
0.054
0.774
15. Surgical approach cures HS 2 (2.0) 6 (7.1) 0.172
16. Management of HS
Easy
Complicated
May need a multidisciplinary approach
0 (0.0)
44 (44.0)
96 (96.0)
0 (0.0)
38 (45.2)
70 (83.3)
1.000
0.866
0.004
HS=hidradenitis suppurativa. N (%) presented for all questions. The χ2 square test was used to compare proportions. *Dermatology compared with all other specialties.
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Interestingly, less experienced GPs, and therefore younger, 
choose more often a multidisciplinary approach of care for 
HS patients.
DISCUSSION
Our data suggested that the disease is well recognized 
by Portuguese GPs, since almost all physicians chose HS 
as the most likely diagnosis in the description of a patient 
with typical symptoms. Moreover, almost all the clinicians, 
regardless of the number of years of clinical practice, 
considered the diagnosis of HS a clinical diagnosis. The 
diagnosis of HS is indeed clinical, usually with no need 
of complementary diagnostic exams or tests. Therefore, 
establishing the diagnosis is theoretically easy: chronic 
and relapsing typical lesions in typical anatomic areas of 
the skin.15 The dissociation between the high percentage 
of right answers in a questionnaire and the long time to 
diagnosis described in the literature is hard to explain. We 
speculate that when confronted with a clinical scenario in 
the real world, maybe the lack of experience assisting HS 
patients or the immediate reassurance of the diagnosis by 
a dermatologist may make GPs consider excluding other 
acute entities before admitting that it might be a chronic 
case of HS.
Nevertheless, regarding the characterization of HS, al-
most half of the GPs that answered the questionnaire did 
not associate HS with disability. This is a very important 
point since the disability caused by HS is substantial16 and 
this fact demonstrated a low knowledge about HS by GPs. 
This low knowledge is also demonstrated by the ques-
tion about prevalence, since only half of the GPs have re-
cognized the correct prevalence of HS, approximately 1%,9 
and the other half of the responders underestimated it.   
The answers regarding the course of action after a 
diagnosis of HS have shown some variability, being the 
“immediate referral plus immediate treatment” the most 
voted option. However, this variability demonstrated that 
GPs need more training regarding HS and how to pro-
ceed in the presence of a patient with an HS diagnosis. 
The same occurred in the question about the therapeu-
tic options, where the variability was also high, demons-
trating the lack of information and uniformization in the 
approach of an HS patient. Notwithstanding, due to the 
complexity and heterogeneity of the disease, each patient 
should be evaluated as a unique case and in some cases 
multiple therapies are needed.15,17-19 Adalimumab is the 
only on-label drug for the treatment of HS, approved for 
adolescent and adult HS patients with moderate to severe 
disease who are intolerant or have had counter-indication 
or inadequate responses to systemic antibiotics for at least 
3 months.20-22 However, only approximately 15% of the cli-
nicians that answered this questionnaire considered biolo-
gical therapy appropriate for HS. These data revealed an 
important lack ok knowledge of HS therapy by GPs.   
Despite the complexity of the disease management, 
less than a half of GPs considered the management 
complicated, yet none considered it easy. It is important to 
note that GPs were conscientious that the surgical approa-
ch did not cure HS.17,18
Risk factors for HS including smoking and obesity are 
well documented.10,16,23,24 However, the number of GPs 
aware of this was low. This can contribute to less effica-
cy in the management of HS: appropriate patient edu-
cation about the complex nature of the disease and its 
risk factors/comorbidities are essential to ensure treat-
ment compliance and efficacy.17 Interestingly, clinicians 
with less than 5 years of clinical practice were more aware 
of this than the more experienced ones. The relevance of 
knowing the association between obesity/smoking and HS 
is related to the holistic approach of this disease: a HS 
patient should be treated in a multidisciplinary way and 
smoking cessation and weight loss strategies belong in the 
sphere of GPs’ competence.
The number of GPs that answered that they manage 
HS patients by themselves was low but relevant: 5% in 
the group with less than 5 years or clinical practice, and 
19% in the group with more than 5 years of clinical prac-
tice. This implies late referral, with the consequent delay 
of starting the correct treatment which will worsen the di-
sease.25 When compared to the results from Belgian and 
Danish GPs, 34.4% and 69.4%,14 respectively, the number 
of Portuguese GPs that manage HS by themselves is much 
lower.  
Beyond late referral, the choice of the correct specialty 
for referral is crucial in the correct management of these 
patients.17 Most GPs correctly referred the patients to Der-
matology. However, approximately 10% of the patients 
were not correctly referred. Once more, the incorrect re-
ferral will delay the start of the appropriate therapeutic 
options and impact on the prognosis. 
Although the percentage of younger doctors conside-
ring a multidisciplinary approach important was higher 
than the more experienced ones, both groups agreed that 
HS may need a multidisciplinary approach. The establish-
ment of a multidisciplinary team for the management of 
HS allows for a complete evaluation of the disease and a 
more comprehensive treatment approach, contributing to 
the appropriate management of HS.14,26,27 Ideally derma-
tologists should coordinate the treatment with the support 
of surgeons, psychologists, endocrinologists, gastroente-
rologists, pain specialists, gynecologists and pediatricians, 
as needed.28 Also, GPs should be included in this team 
in order to evaluate the patient in a holistic manner and 
contributing to lifestyle modification in addition the other 
medical and surgical treatments.15,29 
Considering the differences found between the two 
groups of GPs (cut-off 5 years of clinical practice), there 
were some points that should be evidenced: the impact of 
tobacco use and obesity in HS; the management of HS by 
themselves; and the need of a multidisciplinary approach 
for the management of HS. 
A possible bias of the study was the fact that the 
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questionnaires were applied during two scientific meetings 
with an HS talk announced on the programme. Although 
applied before the specific session regarding HS, the GPs 
attending these scientific meetings could have a particu-
lar interest in Dermatology/hidradenitis suppurativa when 
compared to other GPs that did not attend these meetings. 
As such, there may be a significant selection bias in the 
participant pool, and these GPs may have some previous 
knowledge in Dermatology/HS. Another limitation is that 
the questions addressing diagnosis were created using de-
tailed clinical description and not clinical pictures. In futu-
re studies, clinical pictures as well as initial HS cases could 
also be provided as so many experts feel that GPs may 
experience more trouble diagnosing HS in initial stages.
CONCLUSION
In conclusion, this study showed that the majority of 
the Portuguese GPs were able to identify HS based on the 
description of a clinical case, recognized its chronicity and 
were aware of the need of referral to Dermatology. Never-
theless, approximately 10% of GPs manage HS by them-
selves or do not correctly refer them to Dermatology. Thus, 
this emphasizes the need for education and training of all 
GPs, regardless of the years of clinical practice. This trai-
ning will allow for an accurate and early diagnosis of HS 
and lead to the appropriate referral. Reducing the delay 
in the beginning of the appropriate treatment and the di-
sability associated with this painful condition might impro-
ve the prognosis of the disease, consequently increasing 
the patients’ quality of life and reducing absenteeism and 
healthcare costs.
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